Celltrion Enters Race For Ocrevus Biosimilar, Files Omalizumab In Europe
Roche’s Ocrevus Brought In Sales Of CHF6bn In 2022, Including CHF4.5bn In US
Executive Summary
Celltrion is keeping both eyes firmly on the future as it begins clinical trials for one biosimilar and files another in Europe.
You may also be interested in...
Roche Touts 10-Minute Ocrevus Benefits For MS
A subcutaneous version of Ocrevus is as effective as the intravenous form of Roche's biggest seller, and could boost access of the multiple sclerosis drug where access to intravenous clinics is problematic.
Kashiv Eyeing Next Step As Xolair Biosimilar Passes Another Milestone
New Jersey-based biosimilar and 505(b)(2) specialist Kashiv Biosciences is in the race with multiple Xolair biosimilar sponsors, including frontrunner Celltrion.
Celltrion Is Latest To File Eylea Rival In US
Celltrion has become the latest firm to reveal that it has filed a biosimilar Eylea application with the US FDA in the form of its CT-P42 aflibercept candidate.